Platelet‐Oriented Inhibition in New  TIA  and Minor Ischemic Stroke ( POINT ) Trial: Rationale and design by Johnston, S. Claiborne et al.
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial:
Rationale and design
S. Claiborne Johnston1,2*, J. Donald Easton1, Mary Farrant1, William Barsan3,
Holly Battenhouse4, Robin Conwit5, Catherine Dillon4, Jordan Elm5, Anne Lindblad6,
Lewis Morgenstern3, Sharon N. Poisson7, and Yuko Palesch5
Background Ischemic stroke and other vascular outcomes
occur in 10–20% of patients in the three-months following a
transient ischemic attack or minor ischemic stroke, and many
are disabling. The highest risk period for these outcomes is the
early hours and days immediately following the ischemic
event. Aspirin is the most common antithrombotic treatment
used for these patients.
Aim The aim of POINT is to determine whether clopidogrel
plus aspirin taken <12 h after transient ischemic attack or
minor ischemic stroke symptom onset is more effective in
preventing major ischemic vascular events at 90 days in the
high-risk, and acceptably safe, compared with aspirin alone.
Design POINT is a prospective, randomized, double-blind, mul-
ticenter trial in patients with transient ischemic attack or minor
ischemic stroke. Subjects are randomized to clopidogrel
(600 mg loading dose followed by 75 mg/day) or matching
placebo, and all will receive open-label aspirin 50–325 mg/day,
with a dose of 162 mg daily for five-days followed by 81 mg
daily strongly recommended.
Study Outcomes The primary efficacy outcome is the compos-
ite of new ischemic vascular events – ischemic stroke, myocar-
dial infarction, or ischemic vascular death – by 90 days. The
primary safety outcome is major hemorrhage, which includes
symptomatic intracranial hemorrhage.
Discussion Aspirin is the most common antithrombotic given
to patients with a stroke or transient ischemic attack, as it
reduces the risk of subsequent stroke. This trial expects to
determine whether more aggressive antithrombotic therapy
with clopidogrel plus aspirin, initiated acutely, is more effec-
tive than aspirin alone.
Key words: aspirin, clinical trial, clopidogrel, minor stroke, stroke
prevention, TIA
Introduction and rationale
Transient ischemic attacks (TIAs) are common and often harbin-
gers of disabling ischemic strokes. Between 200 000 and 500 000
TIAs are diagnosed each year in the United States (1,2), while
approximately 795 000 patients experience a new or recurrent
stroke (3).
Rapid recovery from cerebral ischemia is a defining character-
istic of TIA and distinguishes it from completed stroke (1,4–9).
This recovery delineates a distinct pathophysiologic feature that
generally indicates the presence of previously ischemic tissue still
at risk, a characteristic that may be responsible for greater insta-
bility (9,10). The same is true for patients with minor ischemic
strokes. The distinction between minor ischemic stroke and TIA
is unimportant in terms of prognosis, as both groups are at high
short-term risk for new, and often disabling, ischemic stroke and
other vascular events (11–13). These serious vascular outcomes
occur in 10–20% of patients in the three-months following a TIA
or minor ischemic stroke, and the highest risk period for these
outcomes is the early hours and days immediately following the
ischemic event (11–13). Platelet aggregation is an important con-
tributing factor in cerebral ischemia, as in other forms of athero-
thrombotic ischemia. Antiplatelet drugs reduce the risk of
ischemic stroke in this setting. Aspirin is the most common anti-
thrombotic given to patients with a history of stroke or TIA, as it
reduces the risk of subsequent stroke.More aggressive antithrom-
botic therapy, especially dual antiplatelet drugs, in patients with
prior ischemic stroke is commonly associated with a higher risk of
intracranial and other major hemorrhages (14–20). Yet more
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aggressive therapies may be effective in TIA and minor stroke
patients who are at high short-term risk for thrombosis and have
minimal ischemic brain damage that could increase their risk for
bleeding. Aggressive antithrombotic therapy could significantly
reduce the overall burden of stroke if initiated immediately. The
Fast Assessment of Stroke and Transient Ischaemic Attack to
Prevent Early Recurrence (FASTER) pilot trial (21) showed a
trend toward benefit for this approach. The Clopidogrel in High-
risk patients with Acute Non-disabling Cerebrovascular Events
(CHANCE) trial is a large-scale trial evaluating an acute interven-
tion in patients with TIA or nondisabling stroke (22), and the
results should be published soon.
The purpose of the Platelet-Oriented Inhibition in New TIA
and Minor Ischemic Stroke (POINT) study is to determine
whether clopidogrel, when initiated acutely, is more effective than
placebo in preventing major ischemic vascular events in patients
with TIA or minor ischemic stroke, on a background of aspirin.
This article describes the POINT trial design.
Methods
Design and patient population
The design of POINT is shown in Fig. 1. The trial enrolls subjects
18 years of age or older with high-risk TIAs, defined as an ABCD2
(23) score ≥4, or minor ischemic stroke, with a National Institutes
of Health Stroke Scale (24) score ≤3, who can be randomized
within 12 h of the time last known free of new ischemic symp-
toms. Table 1 lists the inclusion and exclusion criteria.
The study is conducted in accordance with the U.S. Food and
Drug Administration (FDA)’s Code of Federal Regulations (CFR
21) and Good Clinical Practice guidelines.
Prior to initiating the study, each site obtains institutional
review board (IRB) approval for the protocol, informed consent
documents, and materials used to recruit subjects. All changes to
the protocol are submitted to each site’s IRB for review and
approval as appropriate. The trial has received an Investigational
New Drug (IND) application waiver from the FDA.
Each eligible patient who wishes to participate is required to
give written informed consent. The consent document explains
the risks and potential benefits of the therapy, the procedures for
the trial, and alternatives to participation. In addition, a video
explanation of the study on an iPad will be provided for potential
enrollees. There is no surrogate consent in the study.
The maximum total sample size for the study is 4150 subjects
from a total of up to 210 investigational sites in the United States
and worldwide.
Face-to-face study visits occur on the day of randomization,
after a possible stroke or myocardial infarction (MI), and at Day
90. Visits are encouraged when serious adverse events occur. Tele-
phone calls occur on Days 7 and 30. Details of the information
collected are available in Supporting Information Table S1 in the
online version of this article.
Randomization
Randomization takes place centrally and electronically via the
WebDCU™ clinical trials management system housed at the
POINT Statistics and Data Coordinating Center at the Medical
University of South Carolina. Subjects are randomized 1:1 (clopi-
dogrel : placebo), treatments balanced within clinical centers
using the blocked-urn method. The randomization computer
program makes the treatment assignment based on the current
status of treatment group distribution within each clinical center
as well as overall balance of treatment assignment.
Treatment
Patients will be randomized into two groups. The first group will
receive a 600-mg loading dose of clopidogrel, followed by 75 mg/
day from Day 2 to Day 90. The second group will receive eight
placebo tablets, matched in appearance and taste to the clopi-
Group 1
Group 2
Clopidogrel 600 mg
Placebo
LOADING DOSE (LD)
Clopidogrel 75 mg from Day 2 to Day 90
ASA 50–325 mg* from Day 2 to Day 90
Placebo from Day 2 to Day 90
ASA 50–325 mg* from Day 2 to Day 90
Day 7
Day 7
M3
M3
R
Aspirin 50–325 mg*
Aspirin 50–325 mg*
Within 12 h of time last known
free of new ischemic symptoms
Selection (head CT/MRI;
inclusion+exclusion criteria verified)
+informed consent signed
Patients with new TIA or
minor ischemic stroke
7-Day Phone
Follow-Up
(7 ± 2 Days)
30-Day Phone
Contact/Follow-Up
(30 ± 2 Days)
90-Day In-Person or Phone
Contact/Follow-Up
(90 ± 14 Days)
Fig. 1 Study flowchart. *Open-label aspirin (at the discretion of the investigator) with dose of 162 mg daily for five-days, followed by 81 mg daily for the
remaining 85 days, strongly recommended.
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dogrel tablets, followed by one placebo tablet daily from Day 2 to
Day 90. Both groups will be given open-label aspirin 50–325 mg/
day: a dose of 162 mg daily for five-days, then the recommended
81 mg daily dose. The first dose of study medication is given as
soon after randomization as possible but no later than 12 h from
symptom onset. Each subject is followed for 90 days from ran-
domization. The trial is expected to complete in seven-years.
Outcomes
The primary efficacy outcome is the composite of new ischemic
vascular events: ischemic stroke, MI, or ischemic vascular death,
up to 90 days. POINT uses the tissue-based definition of stroke
and TIA (25). If a subject has rapid resolution of symptoms and
no brain imaging suggesting tissue infarction, he/she is consid-
ered to have had a TIA. Any brain imaging evidence of infarction
or clinical evidence (such as symptoms persisting beyond 24 h)
qualifies the event as a stroke. Any patient initially diagnosed with
stroke who does not have further brain imaging with evidence of
infarction but has complete resolution of symptoms within 24 h
is considered to have had a TIA.
It often is difficult to determine whether new neurologic defi-
cits that develop after enrollment are due to stroke recurrence
or to stroke progression or infarct growth (26). As the
likely pathophysiology of these events is additional throm-
bosis, potentially amenable to prompt antithrombotic treat-
ment, POINT does not distinguish between recurrence and
progression.
The primary safety outcome is major hemorrhage. The defi-
nition of major bleeding is adapted from the protocol and the
International Society on Thrombosis and Hemostasis (27) and
Prevention Regimen for Effectively Avoiding Second Strokes
(PRoFESS) Trial (18) definitions. Major hemorrhage is one that
results in symptomatic intracranial hemorrhage, intraocular
bleeding causing loss of vision, need for transfusion of two
or more units of red cells or equivalent amount of whole
blood, need for hospitalization or prolongation of an existing
hospitalization, or death. This may include bleeding events
related to surgical procedures. The adjudication committee
evaluates all components of the primary efficacy and safety
outcomes.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Neurologic deficit (based on history or examination) attributed to focal brain ischemia and either:
o High-risk transient ischemic attack: Complete resolution of the deficit at the time of randomization and ABCD2 score ≥4
or
o Minor ischemic stroke: residual deficit with National Institutes of Health Stroke Scale score ≤3 at the time of randomization
• Ability to randomize within 12 h of time last known free of new ischemic symptoms.
• Computed tomography or magnetic resonance imaging of the head ruling out hemorrhage or other pathology, such as vascular malformation,
tumor, or abscess, that could explain symptoms or contraindicate therapy.
• Ability to tolerate aspirin at a dose of 50–325 mg/day.
Exclusion criteria
• Age < 18 years.
• Transient ischemic attack symptoms limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo.
• In the judgment of the treating physician, a candidate for thrombolysis, endarterectomy or endovascular intervention, unless the subject
declines both endarterectomy and endovascular intervention at the time of evaluation for eligibility.
• Receipt of any intravenous or intra-arterial thrombolysis within one-week prior to index event.
• Gastrointestinal bleed or major surgery within three-months prior to index event.
• History of nontraumatic intracranial hemorrhage.
• Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the study period (atrial fibrillation, mechanical heart valve, deep
venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).
• Qualifying ischemic event induced by angiography or surgery.
• Severe noncardiovascular comorbidity with life expectancy less than three-months.
• Contraindication to clopidogrel or aspirin:
Ë Known allergy to clopidogrel or aspirin
Ë Severe renal (serum creatinine >2 mg/dl) or hepatic insufficiency (prior or concurrent diagnosis, with International Normalized Ratio >1·5, or
any resultant complication, such as variceal bleeding, encephalopathy, or icterus)
Ë Hemostatic disorder or systemic bleeding in the past three-months
Ë Current thrombocytopenia (platelet count <100 × 109/l) or neutropenia/granulocytopenia (<1 × 109/l)
Ë History of drug-induced hematologic or hepatic abnormalities
• Anticipated requirement for long-term (>7 days) nonstudy antiplatelet drugs (e.g., dipyridamole, clopidogrel, ticlopidine) or nonsteroidal
anti-inflammatory drugs affecting platelet function (such as prior vascular stent or arthritis).
• Not willing or able to discontinue prohibited concomitant medications.
• Inability to swallow medications.
• At risk for pregnancy: premenopausal or postmenopausal woman within 12 months of last menses without a negative pregnancy test or not
committing to adequate birth control (e.g., oral contraceptive, two methods of barrier birth control, or abstinence).
• Unavailability for follow-up.
• Signed and dated informed consent not obtained from patient.
• Other neurological conditions that would complicate assessment of outcomes during follow-up.
• Ongoing treatment in another study of an investigational therapy, or treatment in such a study within the last 7 days.
• Previously enrolled in the POINT study.
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Several secondary analyses will be performed as described
under Statistical Considerations, including death (all causes),
intracerebral hemorrhage, and minor hemorrhage.
Data safety and monitoring board
The National Institute of Neurological Disorders and Stroke
(NINDS) appointed a Data Safety Monitoring Board (DSMB) as
advisory to the NINDS. The NINDS is responsible for reviewing
the DSMB recommendations to decide whether to continue or
terminate the trial and to determine whether amendments to the
protocol or changes in study conduct are required.
Sample size
The maximum total sample size for the study is 4150 subjects.
With a sample size of 4150 patients, with 530 events, the study has
90% power to detect a relative risk reduction of 23% with a
two-sided alpha of 0·05. The sample size was estimated based on
a hazard ratio (HR) of 0·75 (equivalent to relative risk reduction
of 23%) under the exponential survival distribution (assuming
the proportion of patients with events in the placebo group is
15% at Day 90), with inflation to account for two interim analyses
for efficacy using O’Brien–Fleming-type stopping boundaries.
The intent-to-treat principle will be applied to the primary
outcome analysis, and therefore, the sample size was inflated to
safeguard against 5% lost to follow-up and/or crossover in the
actual treatment received, which may dilute the effect size.
Statistical analyses
Complete details can be found in the Statistical Analysis Plan
(SAP), available in the Supporting Information of the online
version of this article. A final SAP will be issued by the Statistical
and Data Management Center (SDMC) prior to database lock
and before code breaking. The SAP defines all ‘pre-specified,
planned analyses’.
The primary null hypothesis of the trial is that in subjects with
TIA or minor ischemic stroke treated with aspirin 50–325 mg/
day, there is no difference in event-free survival at the Day 90
follow-up in those treated with clopidogrel (600 mg loading dose,
then 75 mg/day) compared with placebo when subjects are ran-
domized within 12 hours of time last known free from new isch-
emic symptoms. The primary outcome is a composite consisting
of ischemic stroke, MI, or ischemic vascular death. The primary
efficacy hypothesis is tested with the log-rank test for equality of
survival curves. This hypothesis is tested with a two-sided level of
significance of 0·05. The primary analysis is intention-to-treat,
with inclusion and treatment group defined per the randomiza-
tion assignment. Subjects missing Day 90 follow-up visits are
censored at the last follow-up assessment date. The primary safety
outcome is major hemorrhage.
A number of other secondary outcomes are planned to be
evaluated separately, including risk of ischemic stroke, all-cause
mortality, intracranial hemorrhage and major hemorrhage, and
the composite of the primary outcome and major hemorrhage.
The influence of index event type (TIA vs. minor stroke), gender,
and race/ethnicity will be evaluated in subgroup analyses.
The analysis strategy outlined for the primary outcome will be
used for most of the secondary analyses. Secondary analyses will
be tested at the two-sided alpha of 0·05 without accounting for
multiplicity. These analyses will be viewed as exploratory hypoth-
eses that may or may not support the results of the primary
analysis.
After one-third and two-thirds of events occur, formal interim
analyses of the primary outcome will be conducted to consider
stopping the trial for overwhelming efficacy or for futility. The
criterion for determination of futility is as follows: if the condi-
tional power (defined as the probability of rejecting the null
hypothesis at the final analysis given the data accumulated so far)
falls below 20%, then the DSMB evaluates all study information
(such as overall recruitment rate and secondary outcome assess-
ment data) to consider stopping the study for futility. Conditional
power is computed under two assumptions: assuming the alter-
native is true and assuming the current trend is true. At the time
of the first interim analysis, the sample size may be re-estimated
solely based on the placebo event rate. If the one-sided upper 99%
confidence limit around the observed placebo rate does not
overlap with those of the assumed rate (15·24%; 95% CI 13·63–
16·85%) based on a sample of 1907 TIA patients from
Kaiser-Permanente Northern California (KPNC) (12), then the
maximum sample size will be re-estimated based on the observed
placebo event rate (assuming the original treatment effect,
HR = 0·75).
Study organization and funding
The principal investigator, who has ultimate responsibility for all
activities and products of the trial and oversees all functions,
directs the trial.
The trial management is a partnership of the University of
California, San Francisco Clinical Coordinating Center (UCSF
CCC) based in the Stroke Sciences Group; the NINDS Neurologi-
cal Emergencies Treatment Trials (NETT) Network, which is
responsible for statistical analyses, data management and over-
sight of NETT sites; and the POINT Clinical Research Collabo-
ration (CRC), supported by The EMMES Corporation, which
manages the non-NETT sites, including the sites outside the
United States.
The NINDS NETT Network, through its SDMC, provides sta-
tistical support and data management services, including reports
to the DSMB and Clinician Events Coordinator, and shielding of
the UCSF CCC, NETT-CCC, and POINT CRC from access to
unblinded data during the trial. The director of the NETT SDMC
is responsible for the randomization protocol, statistical analysis
plan, and final data analysis.
The NINDS funds the POINT. Sanofi contributes clopidogrel
and its placebo at no cost and with no restrictions. The principal
investigator and executive committee will have full access to the
entire dataset at trial completion and are responsible for analysis
and publication in collaboration with the sponsor.
Discussion
People who experience a TIA or minor ischemic stroke are at
substantial risk for amajor stroke and other ischemic events in the
subsequent hours and days. They are most often given aspirin for
anti-atherothrombotic treatment. Others are treated with clopi-
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dogrel or aspirin plus dipyridamole. Recently, more of these
patients are treated with clopidogrel plus aspirin for several days
or weeks, especially if they experience a cerebral ischemic event
while on aspirin. It is not known whether this latter treatment is
efficacious or safe. The POINT trial will evaluate whether clopi-
dogrel plus aspirin is more effective, and acceptably safe, than
aspirin alone in preventing ischemic stroke and other vascular
outcomes in the high-risk period after TIA or minor ischemic
stroke, when the risk for thrombosis is high and the risk for
serious hemorrhage should be low. Whether the trial result is
positive or negative, it will provide valuable clarification of the
appropriate treatment for these patients in whom the best treat-
ment is currently uncertain.
Statements
The authors are solely responsible for the design and conduct of
this study, study analyses, and the drafting and editing of the
paper.
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